Skip to content
OpenCapital
Get started

Black Diamond Therapeutics, Inc. BDTX Q4 2024 Annual earnings

Reported March 6, 2025 · Before market open

EPS-$0.28Beat by $0.03
EPS estimate-$0.31

Next report

Aug 6, 2026 (In 1 week)
EPS estimate-$0.18

Versus estimates

Revenue

Q1 2025$70.0MBeat by $42.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.02Q4 2025-$0.14Beat by $0.04Q3 2025-$0.15Beat by $0.07Q2 2025-$0.19Beat by $0.06Q1 2025$0.98Beat by $0.96
Q4 2024-$0.28Beat by $0.03

Ask the moment Black Diamond Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Black Diamond Therapeutics, Inc. report Q4 2024 earnings?
Black Diamond Therapeutics, Inc. (BDTX) reported Q4 2024 earnings on March 6, 2025 before market open.
What were Black Diamond Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Black Diamond Therapeutics, Inc. reported eps of $-0.28 for Q4 2024.
Did Black Diamond Therapeutics, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.31 by $0.03.
Where can I find Black Diamond Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001701541-25-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.